Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MannKind Breathes Easier After FDA Diabetes Safety Guidance

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

MannKind is reassuring investors that its fast-acting inhaled insulin product Afresa, due for a U.S. filing soon, is likely to satisfy new FDA guidelines for cardiovascular safety of diabetes drugs

You may also be interested in...



Guidance To Cut Diabetes Drug CV Risk Gets First Test With Pending NDAs

FDA’s flexibility in applying its new guidance for cardiovascular safety of diabetes drugs will be tested in coming months as it reviews a handful of pending NDAs and enters into discussions about other drugs in late-stage development.

FDA’s Diabetes Guidance On CV Risk Will Get First Test With Pending NDAs

FDA's flexibility in applying its new guidance for cardiovascular safety of diabetes drugs will be tested in coming months as it reviews a handful of pending NDAs and enters into discussions about other drugs in late stages of development

MannKind Says Inhaled Insulin NDA On Track, Resumes Search For Partner

Afresa Phase III studies are complete, though FDA wants bioequivalence trial to support new inhaler device.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS004044

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel